Citigroup Initiates Coverage On Travere Therapeutics with Neutral Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Carly Kenselaar has initiated coverage on Travere Therapeutics with a Neutral rating and set a price target of $7. The coverage could influence investor sentiment and the stock's market performance in the short term.
November 20, 2023 | 10:55 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Travere Therapeutics received a Neutral rating from Citigroup with a price target of $7, which may affect the stock's performance based on market perception of the analyst's views.
Analyst ratings can influence investor sentiment and stock prices. A Neutral rating suggests that Citigroup does not see significant upside or downside, which may lead to a muted market reaction. The price target of $7 provides a benchmark for investors, but since it is not a bullish or bearish stance, the short term impact is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100